Nyxoah makes the Genio system, an implant that treats obstructive sleep apnea by stimulating the hypoglossal nerve. NYXH reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Cantor Fitzgerald | Target lowered | Buy | |
| Aug 17 | Cantor Fitzgerald | Maintained | Buy | |
| Aug 6 | Piper Sandler | Reiterated | Buy | |
| Jun 17 | Stifel | Target lowered | Hold | |
| May 12 | Stifel | Downgrade | Hold |
Seasonality
How NYXH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in NYXH in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NYXH is in one of them and how their past NYXH trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NYXH in an article yet. Here's the latest on the wider market.
About Nyxoah SA
Nyxoah develops and sells the Genio system, a medical device for treating obstructive sleep apnea, a condition in which the airway repeatedly becomes blocked during sleep. The Genio system is an implant placed through a single incision under the chin that provides bilateral stimulation of the hypoglossal nerve to help keep the airway open. It is intended for adults with moderate to severe sleep apnea who cannot tolerate or adhere to CPAP, the standard mask-based therapy. The company sells to hospitals and sleep physicians in Europe and the United States and is based in Mont-Saint-Guibert.
- Headquarters
- Mont-Saint-Guibert